PROSPECTS OF COMBINING INTERLEUKIN-2 WITH IMMUNE CHECKPOINT INHIBITORS FOR CANCER THERAPY. Voprosy onkologii, v. 66, n. 1, p. 23–28, 1 Jan.2020.